Cargando…

Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report

The clinical efficacy of current therapies for Hepatocellular carcinoma (HCC) are unsatisfactory. In recent years, chimeric antigen receptor (CAR) T-cell therapies have been developed for solid tumors including advanced HCC (aHCC), but limited progress has been made. Glypican-3 is a promising immuno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Hongwei, Xing, Chongyun, Jiang, Songfu, Yu, Kang, Dai, Shengjie, Kong, Hongru, Jin, Yuepeng, Shan, Yunfeng, Yang, Wenjun, Wang, Zhen, Xiao, Jun, Wang, Huamao, Wang, Wei, Li, Zonghai, Shi, Keqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428446/ https://www.ncbi.nlm.nih.gov/pubmed/36059488 http://dx.doi.org/10.3389/fimmu.2022.963031

Ejemplares similares

The correlation factors and prognostic significance of coagulation disorders after chimeric antigen receptor T cell therapy in hematological malignancies: a cohort study
por: Dong, Rujiao, et al.
Publicado: (2022)

Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release
por: Liu, Xuan, et al.
Publicado: (2020)

RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial
por: Fu, Qihan, et al.
Publicado: (2023)

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
por: Zhang, Xin, et al.
Publicado: (2021)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager
por: Bi, Yanyu, et al.
Publicado: (2017)

Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector
por: Liu, Quan, et al.
Publicado: (2017)

Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020)

Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
por: Guo, Xingliang, et al.
Publicado: (2018)

Expression of oncofetal antigen glypican-3 associates significantly with poor prognosis in HBV-related hepatocellular carcinoma
por: Wang, Li, et al.
Publicado: (2016)

Human V(H)-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC
por: Kolluri, Aarti, et al.
Publicado: (2023)

Diagnostic Value of Glypican-3 for Hepatocellular Carcinomas
por: El-Saadany, Sherif, et al.
Publicado: (2018)

Glypican 3-Targeted Therapy in Hepatocellular Carcinoma
por: Nishida, Takahiro, et al.
Publicado: (2019)

Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma
por: Sun, Luan, et al.
Publicado: (2021)

Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma
por: Zhao, Yang, et al.
Publicado: (2019)

Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma(☆)
por: Shih, Tsung-Chieh, et al.
Publicado: (2020)

Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis
por: Sun, Bin, et al.
Publicado: (2017)

Glypicans
por: Filmus, Jorge, et al.
Publicado: (2008)

Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma
por: Zheng, Xiufeng, et al.
Publicado: (2022)

Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype?
por: Shing, Kit, et al.
Publicado: (2020)

Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma
por: Liu, Bao-Jiang, et al.
Publicado: (2020)

Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma
por: Wang, Jian-Yao, et al.
Publicado: (2021)

Diagnostic value of glypican-3, arginase-1 and hepatocyte paraffin antigen -1 in differentiating hepatocellular carcinoma from intrahepatic cholangiocarcinoma
por: Wang, Congrong, et al.
Publicado: (2020)

Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
por: Li, Lin, et al.
Publicado: (2018)

The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Chen, Lei, et al.
Publicado: (2021)

Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma
por: Kaseb, Ahmed Omar, et al.
Publicado: (2016)

Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma
por: Bell, Meghan M., et al.
Publicado: (2020)

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
por: Ikeda, M., et al.
Publicado: (2016)

Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate–advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes
por: Xie, Yong, et al.
Publicado: (2021)

Safety and Efficacy of Transcatheter Arterial Chemoembolization Plus Radiotherapy Combined With Sorafenib in Hepatocellular Carcinoma Showing Macrovascular Invasion
por: Zhao, Yuting, et al.
Publicado: (2019)

Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib
por: Meng, Xiao-Chun, et al.
Publicado: (2018)

A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials
por: Yang, Min, et al.
Publicado: (2022)

Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis
por: Xiao, Wei-Kai, et al.
Publicado: (2014)

Clinical Utility of Plasma Glypican-3 and Osteopontin as Biomarkers of Hepatocellular Carcinoma
por: Lee, Hyun Jung, et al.
Publicado: (2014)

A glypican-3-derived peptide vaccine against hepatocellular carcinoma
por: Sawada, Yu, et al.
Publicado: (2012)

Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma
por: Zhang, Yi-Fan, et al.
Publicado: (2016)

Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma
por: Guo, Meng, et al.
Publicado: (2020)

Association between microRNA-527 and glypican-3 in hepatocellular carcinoma
por: Nomura, Kei, et al.
Publicado: (2021)

Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma
por: Li, Kesang, et al.
Publicado: (2015)

Development and Evaluation of Nomograms to Predict the Cancer-Specific Mortality and Overall Mortality of Patients with Hepatocellular Carcinoma
por: Ni, Xiaofeng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_04uref99vct7g9vmbv56hi3e6e